# Neoadjuvant Pimicotinib Combined With Surgery Versus Upfront Surgery for Diffuse Tenosynovial Giant Cell Tumor

> **NCT07707882** · PHASE2 · NOT_YET_RECRUITING · sponsor: **Second Affiliated Hospital, Zhejiang University, School of Medicine** · enrollment: 84 (estimated)

## Conditions studied

- Tenosynovial Giant Cell Tumor, Diffuse

## Interventions

- **DRUG:** Pimicotinib
- **PROCEDURE:** Tumor resection surgery

## Key facts

- **NCT ID:** NCT07707882
- **Lead sponsor:** Second Affiliated Hospital, Zhejiang University, School of Medicine
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** NOT_YET_RECRUITING
- **Start date:** 2027-10-01
- **Primary completion:** 2029-09-30
- **Final completion:** 2030-09-30
- **Target enrollment:** 84 (ESTIMATED)
- **Last updated:** 2026-07-16


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT07707882

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT07707882, "Neoadjuvant Pimicotinib Combined With Surgery Versus Upfront Surgery for Diffuse Tenosynovial Giant Cell Tumor". Retrieved via MORVS 2026-10-20 from https://api.morvs.ai/clinical/NCT07707882. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*